Culture and Rhetorical Expectations: A Perspective for Technical Communicators
In this article, I discuss how individuals who communicate about technical and scientific topics (i.e., technical communicators) can apply ideas from the theory of rhetoric to communicate more effectively with individuals from other cultures. In so doing, I present a question-based strategy technical communicators can use for planning how they will develop different communication products (e.g., written reports, instructions, websites, etc.) for audiences from cultures other than their own.
Translating the culture of technical documents : some experimental evidence
The approach common in U.S. technical documents, especially the emphasis on user friendliness, is becoming the standard for international communication. In user manuals, industrial proposals, and business plans, that approach strikes a chord among audiences who speak English or other Anglo-Germanic languages. But people whose native language does not fall into that tradition may find the approach inappropriate. American-biased documents may need more than a simple language translation to accommodate such audiences. The documents need to be translated culturally as well. This chapter reports on two experiments conducted at the Eindhoven University of Technology to test techniques of cultural translation: one focused on the writers of such a text, the other on the readers.
Antitumor activities of (2"R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.
(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.